Tirzepatide in New Jersey: Common Questions
Published by New Jersey Trim Clinic · Updated 2026-05-15
The Most Common Tirzepatide Questions From NJ Patients
What is tirzepatide?
Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight management). Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors. This dual mechanism often produces stronger appetite suppression and greater weight loss than semaglutide alone.
How does tirzepatide compare to semaglutide?
Clinical trials show tirzepatide produces average weight loss of 20–22% of body weight vs. 15–17% for semaglutide. Both are highly effective GLP-1-based medications. Your physician will recommend the right option based on your health profile and goals.
How much does tirzepatide cost in New Jersey?
At New Jersey Trim Clinic, tirzepatide programs are $169/mo all-inclusive — medication, physician supervision, follow-up consultations, and direct-to-door shipping from FDA-registered American pharmacies.
Do I need a prescription for tirzepatide in NJ?
Yes. Tirzepatide is a prescription medication requiring physician evaluation. New Jersey Trim Clinic conducts this evaluation via telehealth — no office visits required.
What side effects should I expect?
Similar to semaglutide, the most common side effect is mild nausea during the initial dose escalation period. This typically resolves within 1–2 weeks. Your physician monitors you throughout treatment.
Can I get tirzepatide anywhere in New Jersey?
Yes. New Jersey Trim Clinic serves all 21 NJ counties via telehealth. Medication ships directly to your home.
👉 Start Your Tirzepatide Program · Check If You Qualify
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Supports: Semaglutide 2.4 mg plus lifestyle intervention produced weight loss in the STEP 1 randomized trial; gastrointestinal adverse events were reported.
Evidence limits: The main trial reported mean weight change of −14.9% at 68 weeks. This is not a predicted clinic outcome or proof that every semaglutide formulation has the same results.
- FDA — Wegovy (semaglutide) prescribing information
Supports: The approved product's label describes contraindications including personal or family history of medullary thyroid carcinoma and MEN 2, dose escalation, pregnancy considerations, gastrointestinal reactions, and warnings including pancreatitis, gallbladder disease and kidney injury due to volume depletion.
Evidence limits: This label is for Wegovy, not approval of New Jersey Trim Clinic or a compounded formulation. Individual prescribing decisions require a licensed provider.
- Tirzepatide Once Weekly for the Treatment of Obesity
Supports: The SURMOUNT-1 trial studied tirzepatide at different doses in adults with obesity or overweight without diabetes and reported weight reduction and gastrointestinal adverse events.
Evidence limits: SURMOUNT-1 was placebo-controlled, not a head-to-head comparison with semaglutide. Results do not establish guaranteed outcomes or equivalence of compounded medicines.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Supports: SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide and semaglutide in adults with obesity without diabetes and reported greater average weight reduction with tirzepatide at 72 weeks.
Evidence limits: This was an open-label trial in a defined population. The finding does not determine which treatment is appropriate for an individual, establish clinic outcomes, or validate compounded formulations.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. New England Journal of Medicine. 2021.
Research published in the New England Journal of Medicine reported greater weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo in the studied adults without diabetes.
- Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. New England Journal of Medicine. 2022.
Research published in the New England Journal of Medicine reported dose-dependent weight reduction with tirzepatide versus placebo over 72 weeks in the studied population.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne LJ, Horn DB, le Roux CW, et al.; SURMOUNT-5 Trial Investigators. New England Journal of Medicine. 2025.
Research published in the New England Journal of Medicine reported greater average weight reduction with tirzepatide than semaglutide at the maximum tolerated doses studied in SURMOUNT-5.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.